Journal of Chronic Fatigue Syndrome: Volume 4, Issue 1, 1998

Titles and abstracts for the Journal of Chronic Fatigue Syndrome, Volume 1, Issue 4, 1998.

Volume 4, Issue 1, 1998

• Editorial, by Nancy Klimas & Roberto Patarca
• Circulating Blood Volume in Chronic Fatigue Syndrome
• IgE Concentrations in Chronic Fatigue Syndrome
• Daytime Sleepiness and REM Sleep Abnormalities in Chronic Fatigue: A Case Series
• Coincidental Splenectomy in Chronic Fatigue Syndrome
• Gastrointestinal Manifestations of Chronic Fatigue Syndrome (CFS): Symptom Perceptions and Quality of Life
• Interleukin-6 and Disease: Two Case Reports that Point to the Usefulness of Measuring Cytokine Levels in Clinical Settings

Review articles:

• The Blood-Brain Barrier and Stress

• Pyridostigmine Brain Penetration Under Stress Enhances Neuronal Excitability and Induces Early Immediate Transcriptional Response. (A. Friedman,D. Kaufer, J. Shemer, I. Ilendler, M. Soreq, I. Tur-Kaspa. Nature Medicine 1996;2(12):1382-1385)
• The Gulf War, Stress and a Leaky Blood-Brain Barrier. (Hanin I. Nature Medicine 1996; 2(12): 1307-1308.)

• Clinical Trials

• Intravenous Gammaglobulin is Ineffective in the Treatment of Patients with Chronic Fatigue Syndrome. (Vollmer-Conna U, A. Lloyd, J. Dwyer,D. Wakefield, K. Tymms,D. Hadzi-Pavlovic, I. Hickie. Am J Meet 1997; 103(1): 38-43.)
• Double-Blind Randomized Controlled Trial to Assess the Efficacy of Intravenous Gammaglobulin for the Management of Chronic Fatigue Syndrome in Adolescents. (Rowe K. S. J Psychiatr Res 1997; 31(1): 133-47.)
• An Open Study of the Efficacy and Adverse Effects of Moclobemide in Patients with the Chronic Fatigue Syndrome. (White P.D., K. J. Cleary. Int Clin Psychopharmacol 1997; 12(1): 47-52.)
• Randomised Controlled Trial of Graded Exercise in Patients with the Chronic Fatigue Syndrome. (Fulcher K. Y., P.D. White. BMJ 1997; 314(7095): 1647-52.)
• Amantadine and L-Carnitine Treatment of Chronic Fatigue Syndrome. (Plioplys A. V., S. Plioplys. Neuropsv-chobiology 1997; 35(1): 16-23.)
• Cognitive Behavior Therapy for Chronic Fatigue Syndrome: A Randomized Controlled Trial. (Deale A., S. Wessely, I. Marks, T. Chalder. Am JPsychiatry 1997; 154(3): 408-14.)

• Epidemiology/Natural History Studies

• Epidemiologic Advances in Chronic Fatigue Syndrome. (Levine P. H. J Psychiatr Res 1997; 31(1): 7-18.)
• Precipitating Factors for the Chronic Fatigue Syndrome. (Salit I. E. J Psychiatr Res 1997; 31(1): 59-65.)
• The Natural History of Concurrent Sick Building Syndrome and Chronic Fatigue Syndrome. (Cheser A. C, P. H. Levine. JPsychiatr Res 1997; 31(1): 51-7.)
• Fatiguing Illness Among Employees in Three large State Office Buildings, California, 1993: Was There an Outbreak? (Shefer A., G. W. Rutherford, R. Nisenbaum,D. Koo, L. Steele, K. Fukuda, J. G, Dobbins. J Psychiatr Res 1997; 31(1): 31-43.)
• An Epidemiologic Study of Fatigue with Relevance for the Chronic Fatigue Syndrome. (Fukutla K.,D. Smallwood, K. Wilcox, R.A. Dunn, L.J. Wilson, J. G. Dobbins. J Psychiatr Res 1997; 31(1): 19-29.)
• Chronic Fatigue Syndrome-Aetiological Aspects. (Dickinson C. J. EurJClin Invest 1997; 27(4): 257-67.)
• Epidemic Neuromyasthenia and Chronic Fatigue Syndrome in West Otago, New Zealand: A 10-Year Follow-Up. (Levine P. H, M. J. Holmes, C. Paul, B. A. Ranum, P. G. Snow. Arch Intern Med 1997; 157(7): 750-4.)
• The Prognosis of ROGNOSIS OF Chronic Fatigue and Chronic Fatigue Syndrome: A Systematic Review. (Joyce J., S. Wessely. QJM1997; 90(3): 223-33.)

• General Management of CFS

• Chronic Fatigue Syndrome. A Practical Guide to Assessment and Management. (Sharpe M., S. Wessely, I. Palmer, T. Chalder. Gen Hosp Psychiatry 1997; 19(3): 185-99.)
• Sleep Anomalies in the Chronic Fatigue Syndrome: A Comorbidity Study. (Fischler B., K. De Meirleir, L. Kaufman, R. Cluydts, G. Hoffmann, O. Le Bon. Neuwpsychobiology 1997; 35(3): 115-22.)

• Immunology

• Cytokine Production by Adherent and Non-adherent Mononuclear Cells in Chronic Fatigue Syndrome. (Gupta S., A. Starr,D. See, S. Aggarwal. JPsychiatr Res 1997; 31(1): 149-56.)
• Interleukin-1 Beta, Interleukin-1 Receptor Antagonist, and Soluble Interleukin-1 Receptor Type II Secretion in Chronic Fatigue Syndrome. (Cannon J. G., A. L. Komaroff, S. M. Wolff, L. Fagioli, M.D. Mileno, E. Vannier, L. W. Abad, J. B. Angel. J Clin Immunol 1997; 17(3): 253-61.)
• High Frequency of Autoantibodies to Insoluble Cellular Antigens in Patients with Chronic Fatigue Syndrome. (von Mikecz A., E. M. Tan, L. Gerace,D. S. Buchwald, K. Konstantinov. Arthritis Rheum 1997; 40(2): 295-305.)
• Antimuscle and Anti-CNS Circulating Antibodies in Chronic Fatigue Syndrome. (Plioplys A. V. Neurology 1997; 48(6): 1717-9.)
• The Fibromyalgia Syndrome. (WallaceD.J. Ann Med 1997; 29(1): 9-21.)
• Consequences of Live Poliovirus Vaccine Administration in Chronic Fatigue Syndrome. (Vedhara K, L. K. Borysiewicz, A. R Smith, E. C. Wang, G. B. Clements, R. Jones, M. Jones, ID. Fox, M. B. Llewelyn. JNeuroimmuno 1997; 75(1-2): 183-95.)
• Elevation of Bioactive Transforming Growth Factor-Beta in Serum from Patients with Chronic Fatigue Syndrome. (Bennett A., A. L. Komaroff, P. K. Peterson, P. H. Schur, L. R. Fagioli,D. Buchwald, S. Hu, C. C. Chao. J Clin Immunol 1997; 17(2): 160-6.)
• Markers of Inflammation and Immune Activation in Chronic Fatigue Syndrome. (BuchwaldD., P. Kith, T. Pearlman, M. H. Wener. J Rheumatol 1997; 24(2): 372-6.)
• Chronic Fatigue Syndrome. (Mawle A.C. Immunol Invest 1997; 26(1-2): 269-73.)
• Clinical Improvement in Chronic Fatigue Syndrome is Not Associated with Lymphocyte Subsets of Function or Activation. (Peakman M., S. Wessely, M. Mahalingam, R. Field, A. Deale. Clin Immunol Immunopathol 1997;82(1): 83-91.)
• Evidence for a Novel Low Molecular Weight 2-5A-Dependent RNase L in Chronic Fatigue Syndrome. (Suhadolnik R. 1,D. L. Peterson, K. O'Brien, P. R. Cheney, C. V. T. Herst, N. L. Reichenbach, N. Kon, S.E. Horvath, K. T. lacono, M. E. Adelson, K. De Meirleir, P. DeBecker, R. Charubala, W, Pfleiderer. J Interferon & Cytokine Res 1997; 17: 377-385.)
• Pteridines and Neuroimmune Function and Pathology. (Patarca R., I. Bell, M. A. Fletcher. JCFS 1997; 3(1): 69-86.)

• Neuroendocrinology

• Chronic Fatigue Syndrome: A Disorder of Central Cholinergic Transmission. (Chaudhuri A., T. Majeed, T. Dinan, P. O. Behan. JCFS 1997; 3(1): 3-16.)
• Neuroendocrine Correlates of Chronic Fatigue Syndrome: A Brief Review. (Demitrack M. A. J Psychiatr Res 1997; 31(1): 69-82.)
• Somatomedin C (Insulin-Like Growth Factor 1) Levels in Patients with Chronic Fatigue Syndrome. (Bennett A. L., A. L. Komaroff, R. Guerriero, L. R. Fagioli,D.M. Mayes. J Psyckiatr Res 1997; 31(1): 91-6.)
• Does the Chronic Fatigue Syndrome Involve the Autonomic Nervous System? (Freeman R., A. L. Komaroff. AmJMed 1997; 102(4): 357-64.)
• Changes in Growth Hormone, Insulin, Insulinlike Growth Factors (IGFS), and IGF-Binding Protein-1 in Chronic Fatigue Syndrome. (Allain T J J.P. Miell, S. Wessely, J. Butler, A. Checkley, J. Jones, P. Coskeran, J.A. Beam. BiolPsychiatry 1997; 41(5): 567-73.)

• Virology

• Electron Microscopic Immunocytological Profiles in Chronic Fatigue Syndrome. (Holmes M. J., B. Carlisle, J.P. Cross, R.A. Easingwood,D. S. Diack. J Psychiatr Res 1997; 31(1): 115-22.)
• Evidence for Enteroviral Persistence in Humans. (GalbraithD. N., G. B. Clements, C. Nairn‥/Gen Virol 1997; 78 (Pt 2): 307-12)
• Chronic Parvovirus B19 Infection Resulting in Chronic Fatigue Syndrome: Case History and Review. (Jacobson S. K., K. Mclntosh, G. M. Thome, J. S. Daly. Clin Infect Dis 1997; 24(6): 1048-51.)
• Detection of RNA Sequences in Cultures of a Stealth Virus Isolated from the Cerebrospinal Fluid of a Health Care Worker with Chronic Fatigue Syndrome: Case Report. (Martin W. J. Pathobiology 1997; 65(1): 57-60.)

• Neurocognitive and Neuropsychiatric Studies

• The Relation of Sleep Difficulties to Fatigue, Mood and Disability in Chronic Fatigue Syndrome. (Morriss R. K., L. Battersby, A. J. Wearden. J Psychosom Res 1997; 42(6): 597-605.)
• Cognitive Functioning is Impaired in Patients with Chronic Fatigue Syndrome Devoid of Psychiatric Disease. (DeLuca J., B. H. Natelson, S. P. Ellis, S. K. Johnson. JNeurol Neurosurg Psychiatry 1997; 62(2): 151-5.)
• Sudden vs. Gradual Onset of Chronic Fatigue Syndrome Differentiates Individuals on Cognitive and Psychiatric Measures. (DeLuca J., B.H. Natelson, S.P. Ellis, S.K. Johnson. JPsychiatr Res 1997; 31(1): 83-90.)
• Cognitive Slowing and Working Memory Difficulties in Chronic Fatigue Syndrome. (Marshall P.S., C.H. Schenck, P.K. Peterson, A. Callies, M. Forstot. Psychosom Med 1997; 59(1): 58-66.)
• Cognitive Performance and Complaints of Cognitive Impairment in Chronic Fatigue Syndrome (CFS). (Wearden A., L. Appleby. PsycholMed 1997; 27(1): 81-90.)
• Neuropsychological and Psychological Functioning in Chronic Fatigue Syndrome. (Kane R.L., R.K. DiPino, N.M. Gantz. Neuropsychiatry Neumpsychol Behav Neurol 1997; 10(1): 25-31.)
• The Quality of Life of Persons with Chronic Fatigue Syndrome. (Anderson J. S., C. E. Ferrans. 1 Nerv Ment Dis 1997; 185(6): 359-67.)
• The Marital Relationship and Health in Women with Chronic Fatigue and Immune Dysfunction Syndrome: Views of Wives and Husbands. (Goodwin S. S. NursRes 1997; 46(3): 138-46.)
• Screening for Psychiatric Disorders in Chronic Fatigue and Chronic Fatigue Syndrome. (BuchwaldD., K. Schmaling, W. Katon, P. Kith, T. Pearlman. JPsychosom Res 1997; 42(1): 87-94.)
• A View of the Violence Contained in Chronic Fatigue Syndrome. (Bennett A. J. J Anal Psychol 1997; 42(2): 237-51.)
• Coniunctio-in Bodily and Psychic Modes: Dissociation, Devitalization and Integration in a Case of Chronic Fatigue Syndrome. (Holland P. J Anal Psychol 1997; 42(2): 217-36.)
• A Body with Chronic Fatigue Syndrome as a Battleground for the Fight to Separate from the Mother. (Simpson M. J Anal Psychol 1997; 42(2): 201-16.)
• Chronic Fatigue Syndrome/Myalgic Encephalomy-elitis as a Twentieth-Century Disease: Analytic Challenges. (Simpson M., P. Holland, A. Bennett. J Anal Psychol 1997; 42(2): 191-9.)

See also

• Journal of Chronic Fatigue Syndrome for other Issues

chronic fatigue (CF) - Persistent and abnormal fatigue is a symptom, not an illness. It may be caused by depression, multiple sclerosis, fibromyalgia, chronic fatigue syndrome or many other illnesses. The term "chronic fatigue" should never be confused with the disease chronic fatigue syndrome.

See chronic fatigue syndrome.

cytokine any class of immunoregulatory proteins secreted by cells, especially immune cells. Cytokines are small proteins important in cell signaling that modulate the immune system. (Learn more: me-pedia.org)

stress Stress can by either physical or psychological, or both. Stress is either 1) a state of emotional or psychological strain or 2) the physical stress (pressure or tension) that a physical object such the human body is placed under, e.g., a stress test is a medical test that monitors the cardiovascular system during strenuous exercise.

randomized controlled trial (RCT) - A trial in which participants are randomly assigned to two groups, with one group receiving the treatment being studied and a control or comparison group receiving a sham treatment, placebo, or comparison treatment.

randomized controlled trial (RCT) - A trial in which participants are randomly assigned to two groups, with one group receiving the treatment being studied and a control or comparison group receiving a sham treatment, placebo, or comparison treatment.

The BMJ (previously the British Medical Journal) is a weekly peer-reviewed medical journal.

BMJ The BMJ (previously the British Medical Journal) is a weekly peer-reviewed medical journal.

cognition Thought processes, including attention, reasoning, and memory.

antagonist A chemical that reduces or helps block the activity of another chemical in the body. For example, most antihistamines are H1 antagonists because they block the H1 histamine receptor, which helps relieve allergy symptoms. The opposite of an agonist.

autoantibody An antibody that works against the body's own antigens, a hallmark of autoimmune diseases. Autoantibodies are the opposite of an antibodies.

central nervous system (CNS) - One of the two parts of the human nervous system, the other part being the peripheral nervous system. The central nervous system consists of the brain and spinal cord, while the peripheral nervous system consists of nerves that travel from the central nervous system into the various organs and tissues of the body.

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

serum The clear yellowish fluid that remains from blood plasma after clotting factors have been removed by clot formation. (Blood plasma is simply blood that has had its blood cells removed.)

cholinergic Involving the neurotransmitter acetylcholine. Cholinergic side effects include diarrhea, blurred vision, decreased intraocular pressure, contricted pupil in the eyes, sweating, increased saliva and mucus on the lungs, bronchial constriction, increased gastrointestinal tone, decreased blood pressure, slow heart rate, and contraction of bladder detrusor muscle. muscle spasms/cramps, low blood pressure, slowed heart rate, nausea and vomiting, increased saliva and sweating, shortness of breath, and urinating more often.

enterovirus A genus of RNA viruses which typically enter the body through the respiratory or gastrointestinal systems and sometimes spread to the central nervous system or other parts of the body, causing neurological, cardiac, and other damage. Since the first reports of myalgic encephalomyelitis (ME), enteroviruses have been suspected as a cause of ME. Enteroviruses have also been implicated as the cause of Type I diabetes, congestive heart failure, and other conditions. Enteroviruses include poliovirus, coxsackieviruses, and many others. New enteroviruses and new strains of existing enteroviruses are continuously being discovered. (Learn more: viralzone.expasy.org)